Evidence map›Paper›PMID 39496388›Full record

ArticleExperimental animals2025

Transcriptomics and metabolomics analysis of the pathogenesis of a novel hyperlipidemia-susceptible rat strain.

Xiufeng Ai, Qian Zhang, Quanxin Ma, Mingsun Fang, Keyan Zhu, Yueqin Cai, Qinqin Yang, Lizong Zhang

Abstract read
In one paragraph

Article in Experimental animals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiufeng AiAnimal Experimental Research Center/Institute of Comparative Medicine, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang 310053, P.R. China.
Qian ZhangAnimal Experimental Research Center/Institute of Comparative Medicine, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang 310053, P.R. China.
Quanxin MaKey laboratory of silkworm and bee resource utilization and innovation of Zhejiang Province, College of Animal Sciences, Zhejiang University, 866 Yuhangtang Road, Xihu District, Hangzhou, Zhejiang 310058, P.R. China.
Mingsun FangAnimal Experimental Research Center/Institute of Comparative Medicine, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang 310053, P.R. China.
Keyan ZhuAnimal Experimental Research Center/Institute of Comparative Medicine, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang 310053, P.R. China.
Yueqin CaiAnimal Experimental Research Center/Institute of Comparative Medicine, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang 310053, P.R. China.
Qinqin YangDepartment of Experimental Animals, Zhejiang Academy of Traditional Chinese Medicine, 132 Tianmushan Road, Xihu District, Hangzhou, Zhejiang 310007, P.R. China.
Lizong ZhangAnimal Experimental Research Center/Institute of Comparative Medicine, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang 310053, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wistar-SD Hypercholesterolemia (WSHc) Rat is a novel hyperlipidemia-susceptible rat that we discovered and bred earlier, which can be used as an ideal animal model for the study of non-alcoholic fatty liver disease (NAFLD). However, its pathogenesis of hyperlipidemia and genetic and biological characteristics need to be further investigated. In the current study, WSHc rats were fed a high-fat diet (HFD) and standard chow (SC), with age-matched Wistar rats as the control group undergoing the same treatment, followed by serum lipid level measurement. It was found that HFD-fed WSHc rats developed dyslipidemia. Transcriptomic analysis was performed to detect genes associated with cholesterol metabolism in the liver, and 119 differentially expressed genes were discovered through bioinformatics analysis and molecular biology verification. Additionally, Srebf1 was identified as a HUB gene and Nr1d1 as an independent key gene using the protein-protein interaction network and one-cluster clustering analysis. The two genes had also been further validated in molecular biology experiments and were consistent with transcriptomic results. Serum lipid metabolomics analysis identified 7 lipid subclasses and 84 lipid molecules using UHPLC-Q-TOF/MS. There were 62 and 70 lipid molecules with significant differences in the metabolic profiles of serum lipid mediators in the WSHc+HFD group compared to the WSHc+SC and Wistar+HFD groups, respectively, and the differential metabolites were mainly produced via sphingolipid and glycerophospholipid metabolism. In sum, the hypercholesterolemia model can be established with WSHc rats after the HFD induction, and the pathogenesis involves the Srebf1 and Nr1d1 genes and the sphingolipid and glycerophospholipid metabolism pathways.

Indexed as

Disease Models, AnimalHypercholesterolemiaHyperlipidemiasMetabolomicsNon-alcoholic Fatty Liver DiseaseTranscriptomeAnimalsDiet, High-FatGene Expression ProfilingLipid MetabolismLiverMaleRatsRats, Sprague-DawleyRats, Wistaranimal modelhyperlipidemialipidomicstranscriptomicsWistar-SD Hypercholesterolemia (WSHc) rats

Identifiers

PMID39496388
PMCPMC12044359

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.